LENZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
LENZ Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$3.30+0.03 (+0.92%)
Close on Oct 19, 2026
- Market cap
- $103.54M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$34.96 (−91.37%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
LENZ Therapeutics, Inc. grew revenue 329.5% to $21.48M over the twelve months to Jun 30, 2026. Free cash flow was -$114.42M.
Revenue
$21.48M
+329.5% vs. a year earlier
Operating income
-$135.66M
TTM Q2 2026
Free cash flow
-$114.42M
TTM Q2 2026
EPS, diluted
-$4.08
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $103.54M
- P/E ratio
- –
- Price to sales
- 4.82
- Price to book
- 0.47
- Dividend yield
- –
- Free cash flow yield
- -110.51%
Fundamentals
- Revenue
- $21.48M
- Net income
- -$126.00M
- EPS, diluted
- -$4.08
- Free cash flow
- -$114.42M
- Book value per share
- $6.99
- Diluted shares
- 31M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
$21.48M+329.5% YoY
Gross profit
–
Operating income
-$135.66M
Net income
-$126.00M
EPS, diluted
-$4.08
Free cash flow
-$114.42M
Reported periodTrailing twelve months